Tectonic Therapeutic, Inc.
- Open
- 34.13
- Day high
- 34.57
- Day low
- 31.88
- Prev close
- 34.38
- Volume
- 113K
- Mkt cap
- $649M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.8
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$63K over the last 3 months (0 open-market buys, 2 sales)
- 🏛Institutions accumulating (13F)
Tectonic Therapeutic, Inc. (TECX) is a Healthcare company listed on NASDAQ. The stock is up 67% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 2 sales (SEC Form 4).
Tectonic Therapeutic, Inc. (TECX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TECX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-1.16 | $-1.34 | -15.5% | — | — |
| Nov 6, 2025 | $-1.05 | $-1.02 | +2.9% | — | — |
| Aug 7, 2025 | $-0.98 | $-1.07 | -9.2% | — | — |
| May 8, 2025 | $-1.10 | $-0.93 | +15.5% | — | — |
| Mar 20, 2025 | $-1.39 | $-0.84 | +39.6% | — | — |
| Nov 7, 2024 | $-0.84 | $-1.20 | -42.9% | — | — |
| Aug 14, 2024 | $-1.96 | $-3.81 | -94.4% | — | — |
| May 9, 2024 | $-4.32 | $-1.80 | +58.3% | — | — |
| Mar 14, 2024 | $-4.04 | $-2.40 | +40.6% | — | — |
| Jun 29, 2019 | — | $-8.01 | — | — | — |
| Mar 30, 2019 | — | $-8.59 | — | — | — |
| Sep 29, 2018 | — | $-5.86 | — | — | — |
TECX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 23, 2026 | REICIN ALISEdirector, officer: Chief Executive Officer | Tax | 924 | $30.34 |
| Jun 12, 2026 | Lochner Danielofficer: Chief Financial Officer | Grant | 7,500 | $16.80 |
| Jun 10, 2026 | SPRINGER TIMOTHY Adirector, 10 percent owner: | Grant | 10,200 | $28.56 |
| Jun 10, 2026 | Tipirneni Praveen P.director | Grant | 10,200 | $28.56 |
| Jun 10, 2026 | Chutter Jessica Carolinedirector | Grant | 20,400 | $29.10 |
| Jun 10, 2026 | Donenberg Phillip B.director | Grant | 10,200 | $28.56 |
| Jun 10, 2026 | Vitorovic Stefandirector | Grant | 10,200 | $28.56 |
| May 6, 2026 | Ruddy Marcella K.officer: Chief Medical Officer | Sell | 1,065 | $30.00 |
| Apr 3, 2026 | Ruddy Marcella K.officer: Chief Medical Officer | Sell | 1,000 | $31.05 |
| Apr 3, 2026 | Nader Francoisdirector | Grant | 20,400 | $30.78 |
| Mar 9, 2026 | Ruddy Marcella K.officer: Chief Medical Officer | Sell | 10,000 | $30.00 |
| Mar 9, 2026 | McNamara Peterofficer: Chief Scientific Officer | Option | 2,500 | $2.38 |
| Mar 9, 2026 | McNamara Peterofficer: Chief Scientific Officer | Option | 215 | $14.71 |
| Mar 9, 2026 | McNamara Peterofficer: Chief Scientific Officer | Sell | 6,047 | $30.00 |
| Mar 9, 2026 | McNamara Peterofficer: Chief Scientific Officer | Sell | 215 | $35.00 |
Source: TECX SEC Form 4 filings, latest Jun 23, 2026. For informational purposes only — not investment advice.
See the full TECX insider & 13F page →Tectonic Therapeutic, Inc. company profile
Overview
Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a clinical-stage biotechnology company founded to develop innovative therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs). Based in Watertown, Massachusetts, the company has built its operations around its proprietary GEODe technology platform, which enables the discovery and development of GPCR-targeted biologic medicines. As a pre-revenue biotechnology company, Tectonic is currently advancing multiple drug candidates through clinical trials, with its lead program focused on heart failure treatment entering Phase 1 studies.
Business
Tectonic Therapeutic operates in the biotechnology sector, specifically focusing on drug discovery and development targeting G-protein coupled receptors (GPCRs). GPCRs are a large family of cell surface proteins that play crucial roles in cellular communication and are involved in numerous physiological processes including hormone signaling, neurotransmission, and immune responses. These receptors are considered one of the most important classes of drug targets in modern medicine, with approximately 35% of all marketed drugs targeting GPCRs. The company's core technology is the GEODe platform, a proprietary system designed to discover and develop therapeutic proteins and antibodies that can precisely modulate GPCR activity. Traditional small molecule drugs often lack the specificity needed to target GPCRs effectively, while Tectonic's approach uses larger protein-based therapeutics that can achieve more selective and potent effects. Tectonic's current pipeline includes several distinct programs: 1. An RXFP1 agonist program targeting heart failure with preserved ejection fraction (HFpEF), currently in Phase 1a and 1b clinical trials. This represents the company's most advanced program and addresses a significant unmet medical need, as HFpEF affects millions of patients worldwide with limited treatment options. 2. A GPCR antagonist program for hereditary hemorrhagic telangiectasia, a rare genetic disorder causing abnormal blood vessel formation. 3. A bi-functional GPCR modulator targeting fibrosis, which could address multiple fibrotic diseases across different organ systems. 4. Additional GPCR modulators in earlier stages of development for undisclosed indications. As a clinical-stage company, Tectonic currently generates no revenue, with all programs still in development phases. The company's value proposition lies entirely in its pipeline potential and the broad applicability of its GEODe platform technology.
Revenue model
Tectonic Therapeutic currently operates under a typical biotechnology business model with no revenue generation, as all programs remain in clinical development. The company's future revenue model will likely center on product sales of approved therapeutics, licensing agreements with pharmaceutical partners, and potentially milestone payments and royalties from collaboration deals. The primary customers for Tectonic's future products will be healthcare providers, hospitals, and patients through the traditional pharmaceutical distribution system. Given the company's focus on both rare diseases (hereditary hemorrhagic telangiectasia) and large market opportunities (heart failure), the customer base could range from specialized treatment centers to broad cardiology practices. Several factors could significantly impact Tectonic's future margins and profitability. Positive factors include the company's focus on GPCR targets, which historically command premium pricing due to their therapeutic importance and the technical barriers to developing effective GPCR-targeted biologics. The company's proprietary GEODe platform could provide competitive advantages and higher margins compared to generic approaches. Additionally, success in rare disease indications often allows for orphan drug pricing strategies with higher margins. Negative factors include the inherent risks of biotechnology development, where clinical trial failures could eliminate entire revenue streams. The company faces competition from established pharmaceutical companies with greater resources and multiple GPCR programs. Manufacturing costs for protein-based therapeutics are typically higher than small molecules, potentially compressing margins. Regulatory hurdles for biologics are substantial, requiring extensive clinical data and potentially delaying market entry. The company's current cash burn rate of approximately $60 million annually indicates significant ongoing operational expenses that will need to be supported until revenue generation begins.
Competitive moat
Tectonic Therapeutic's competitive moat appears relatively narrow, typical of early-stage biotechnology companies. The company's primary potential moat lies in its GEODe technology platform, which could provide proprietary advantages in discovering and developing GPCR-targeted biologics. If successful, this platform could create intellectual property barriers and technical expertise that competitors would find difficult to replicate quickly. The company's focus on GPCRs does provide some strategic positioning, as these targets are notoriously difficult to drug effectively with traditional approaches. Tectonic's protein-based therapeutic approach could offer advantages over small molecule competitors in terms of specificity and potency. However, this moat is largely theoretical until clinical success is demonstrated. Significant competitive threats include large pharmaceutical companies with substantially greater resources, established GPCR programs, and proven track records in bringing biologics to market. Companies like Amgen, Genentech, and other major biotechnology firms have extensive experience with protein therapeutics and could potentially develop competing approaches. The biotechnology sector is also characterized by rapid technological advancement, meaning Tectonic's platform advantages could be eroded by newer technologies or approaches. The company's moat is further weakened by its pre-revenue status and dependence on clinical trial success. Unlike established pharmaceutical companies with diversified revenue streams, Tectonic faces binary outcomes where clinical failures could eliminate competitive advantages entirely. The company's current market position is more accurately described as having potential competitive advantages rather than established moats, with the strength of any future moat heavily dependent on successful clinical development and regulatory approval of its pipeline candidates.
Risks & safety
Tectonic Therapeutic presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong liquidity but significant execution risks. • Liquidity and Solvency: The company maintains an exceptionally strong cash position with $306 million in cash and short-term investments as of Q1 2025, providing substantial runway given current burn rates of approximately $60 million annually. Current ratio of 22.9 indicates excellent short-term liquidity, while minimal debt (debt-to-equity ratio of 0.009) eliminates solvency concerns in the near term. • Cash Burn Analysis: With quarterly operating cash flow losses of $13 million in Q1 2025, the company has approximately 5-6 years of runway at current spending levels, though burn rates may increase as clinical programs advance to later stages requiring larger, more expensive trials. • Valuation Considerations: Traditional valuation metrics are not meaningful for pre-revenue biotechnology companies. The company's market capitalization of approximately $430 million represents a premium to book value (P/B ratio of 1.01), suggesting investors are pricing in significant pipeline potential rather than tangible assets. • Additional Risk Factors: Binary clinical trial outcomes create substantial downside risk, with potential for complete value destruction upon program failures. The company's entire value proposition depends on successful clinical development and regulatory approval, areas with historically high failure rates in biotechnology.
Recent development
Based on the available financial data, Tectonic Therapeutic has demonstrated several key strategic developments over recent years. The company has significantly strengthened its financial position, with cash and short-term investments increasing dramatically from $29 million in 2023 to $141 million by the end of 2024, and further to $306 million in Q1 2025. This substantial cash infusion likely resulted from equity financing activities, providing the company with extended runway to advance its clinical programs. The company's research and development spending has remained consistently high, with annual losses of approximately $58 million in 2024 compared to $43 million in 2023, indicating accelerated investment in clinical development activities. This increased spending pattern suggests the company is actively advancing its pipeline programs, particularly the RXFP1 agonist program for heart failure with preserved ejection fraction, which has progressed into Phase 1a and 1b clinical trials. Operationally, Tectonic has maintained a lean organizational structure with relatively stable quarterly burn rates, suggesting disciplined capital allocation focused on core development activities rather than excessive infrastructure expansion. The company's strategic focus appears concentrated on advancing its lead programs through critical clinical milestones while leveraging its GEODe platform technology to potentially expand its pipeline or attract partnership opportunities. The substantial cash raise positions Tectonic to execute on its clinical development strategy without immediate financing pressures, allowing management to focus on operational execution and clinical trial advancement rather than fundraising activities. This financial stability provides the company with optionality to pursue strategic partnerships or licensing deals from a position of strength rather than necessity.
TECX company profile · for informational purposes only — not investment advice.
Track TECX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free